Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
hemic and lymphatic diseases | D006425 |
immune system diseases | D007154 |
Expiration | Code | ||
---|---|---|---|
tisagenlecleucel, Kymriah, Novartis Pharmaceuticals Corporation | |||
2029-05-27 | Orphan excl. |
Code | Description |
---|---|
Q2042 | Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 9 | 6 | 3 | — | 5 | 20 |
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 7 | 4 | 2 | — | 6 | 18 |
Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | 2 | 6 | 1 | — | — | 9 |
Follicular lymphoma | D008224 | — | C82 | 2 | 3 | 1 | — | 3 | 8 |
B-cell lymphoma | D016393 | — | — | 4 | 3 | 1 | — | 2 | 8 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 3 | 4 | 1 | — | — | 7 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 5 | — | 1 | — | 1 | 7 |
Mantle-cell lymphoma | D020522 | — | C83.1 | 2 | 2 | 1 | — | 1 | 5 |
Burkitt lymphoma | D002051 | — | C83.7 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple myeloma | D009101 | — | C90.0 | 2 | 1 | — | — | 1 | 4 |
Lymphoma | D008223 | — | C85.9 | 2 | 1 | — | — | 2 | 4 |
B-cell leukemia | D015448 | — | — | 2 | 2 | — | — | 1 | 3 |
Myeloid leukemia acute | D015470 | — | C92.0 | 1 | 1 | — | — | — | 1 |
Healthy volunteers/patients | — | — | — | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Biphenotypic leukemia acute | D015456 | — | C95.0 | 2 | — | — | — | 1 | 3 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | — | — | — | — | 2 |
Leukemia | D007938 | — | C95 | 2 | — | — | — | — | 2 |
Hodgkin disease | D006689 | — | C81 | 2 | — | — | — | — | 2 |
Prolymphocytic leukemia | D015463 | — | — | 1 | — | — | — | 1 | 2 |
Residual neoplasm | D018365 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cytokine release syndrome | D000080424 | — | D89.83 | — | — | — | — | 1 | 1 |
Myocarditis | D009205 | — | I51.4 | — | — | — | — | 1 | 1 |
Lymphoid leukemia | D007945 | — | C91 | — | — | — | — | 1 | 1 |
Drug common name | Tisagenlecleucel |
INN | tisagenlecleucel |
Description | Tisagenlecleucel, sold under the brand name Kymriah, is a CAR T cells medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses the body's own T cells to fight cancer (adoptive cell transfer).
|
Classification | Cell |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | 1986438 |
ChEMBL ID | CHEMBL3301574 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB13881 |
UNII ID | Q6C9WHR03O (ChemIDplus, GSRS) |